Start here if you're new
what it is
Dianthus is a clinical-stage biotech trying to turn one lead antibody into treatments for severe autoimmune diseases.
how it gets paid
Last year Dianthus Thera made $2M in revenue. legacy collaboration and other revenue was the main engine at $0.8M, or 40% of sales.
why growth slowed
Revenue fell 67.3% last year. The numbers show the same reality as before: this is still a clinical-stage company with little operating revenue and ongoing losses tied to development spending.
what just happened
Revenue was just $2M, while EPS came in at -$2.68.
At a glance
B balance sheet — gets the job done, barely
25/100 earnings predictability — expect surprises
-$2.55 fy2024 eps est
$6M fy2024 rev est
n/a operating margin
xvary composite: 54/100 — below average
What they do
Dianthus is a clinical-stage biotech trying to turn one lead antibody into treatments for severe autoimmune diseases.
The moat is not current sales. It is DNTH103, the lead asset, plus a balance sheet with just $1 million of long-term debt, or 0% of capital. Clinical-stage biotech moat → one promising molecule plus enough cash to keep testing it → so what: if the data holds, you own optionality before revenue exists.
How they make money
$2M
annual revenue · their business grew -67.3% last year
legacy collaboration and other revenue
$0.8M
flat
research support and service revenue
$0.5M
dn
license and option-related revenue
$0.3M
up
development milestone recognition
$0.2M
flat
other operating revenue
$0.2M
dn
The products that matter
Phase 3 drug candidate
DNTH103
single clinical asset · CIDP focus
it's the only asset that matters today, targeting roughly 40,000 CIDP patients in the US. if DNTH103 works, the story changes. if it does not, most of the story disappears.
one-asset bet
Key numbers
$2M
trailing revenue
That is the current business size per EDGAR and Yahoo Finance. You are paying a biotech premium for a company with almost no commercial engine.
$4B
market cap
This is what the market says the future pipeline is worth today, despite the tiny current revenue base.
n/a
operating margin
Prior margin KPI failed sanity check — verify in filings. Operating margin → profit after running the business → so what: the company is burning cash at a scale that makes revenue almost irrelevant right now.
$1M
long-term debt
Debt is minimal, which matters because clinical-stage biotechs usually need flexibility more than leverage.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 2 — safer than 80% of stocks
- price stability 5 / 100
- long-term debt $1M (0% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for DNTH right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue was just $2M, while EPS came in at -$2.68.
The numbers show the same reality as before: this is still a clinical-stage company with little operating revenue and ongoing losses tied to development spending.
$2M
revenue
$2.68
eps
n/a
n/a
the number that mattered
The number that mattered was $2 million of quarterly revenue, because against a roughly $4 billion market cap it tells you the stock still trades on hope, not sales.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is CAPTIVATE trial failure for DNTH103 in CIDP. This is not a diversified pipeline story. It is one clinical asset carrying a $4B equity value.
med
trial failure would break the thesis fast
DNTH103 is the company's only clinical asset. If the CAPTIVATE Phase 3 study disappoints, the business is left with $2M in revenue and a $162.3M annual net loss. That is not a cushion. That is a reminder of what you actually own.
Most of the $4B valuation is tied to success on one program.
med
cash burn can turn into dilution
R&D spend was $145.6M last year against just $2M of reported revenue. Even with only $1M of long-term debt, this model likely needs outside capital if timelines stretch or costs rise.
The risk is not insolvency first. It is issuing more shares before the science settles the question.
med
insider selling muddies the signal
The CEO sold 122,918 shares and an EVP sold $2.76M of stock within the last three days. Executives sell for many reasons. In a single-asset biotech ahead of major catalysts, you still notice it.
It does not prove the science is weak. It does raise the bar for trusting the current valuation.
a failed readout, a delayed timeline, or a dilutive raise would all hit the same place: the idea that one drug justifies a $4B market cap.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
CAPTIVATE timeline discipline
The March 9, 2026 go decision matters because it keeps the Phase 3 path alive. From here, any slippage in enrollment, dosing, or readout timing matters more than a normal quarterly report.
risk
next financing move
A $162.3M net loss and $145.6M of R&D spend tell you the capital question is still alive. If management raises equity before a major catalyst, your ownership gets thinner.
trading
whether insider selling continues
One sale can be personal planning. A pattern is different. Watch whether sales keep showing up while the stock tries to rebuild confidence off the $43.77 level.
market reality
valuation versus actual revenue
The company carries a ~$4B market cap on $2M of trailing revenue and a $6M estimate for fy2024. That gap is the whole story: you are paying almost entirely for future approval odds.
Analyst rankings
earnings predictability
25 / 100
in human-speak, analysts do not have a stable business to model here. expect estimate changes as trial timelines move.
risk rank
2
this score says the balance sheet is relatively sound. it does not mean the clinical setup is low risk.
price stability
5 / 100
the chart is doing biotech things. translation: expect violent moves around filings and trial milestones.
source: institutional data
Institutional activity
institutional ownership data for DNTH is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$44
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive